The cancer treatment focused Provectus Pharmaceuticals Inc (NYSEMKT:PVCT) has announced a new addition to its strategic advisory board. The announcement comes on the wake of the elevation of the stock to a senior capital market – NYSEMKT. The company announced that Jacob M. Plotsker will join its strategic board to help guide the company through growth and maximization of shareholder value. Provectus Pharmaceuticals Inc (NYSEMKT:PVCT) weekly performance is -4.68%. On last trading day company shares ended up $2.24. Analysts mean target price for the company is $3.50. Provectus Pharmaceuticals Inc (NYSEMKT:PVCT) distance from 50-day simple moving average (SMA50) is -6.99%.
Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, announced the closing of its previously announced sale of its SUMAVEL(R) DosePro(R) Needle-free Delivery System (sumatriptan injection) product line to Endo International plc (Nasdaq:ENDP) for $85 million in cash and milestone payments of up to $20 million. Zogenix, Inc. (NASDAQ:ZGNX) shares fell -5.37% in last trading session and ended the day on $1.94. ZGNX Gross Margin is 39.20% and its return on assets is -127.10%. Zogenix, Inc. (NASDAQ:ZGNX) quarterly performance is -57.92%.
Intercept Pharmaceuticals, Inc (NASDAQ:ICPT)’s shares tumbled 14.1% after a report from The Street disclosed that the company had information about the occurrence of abnormal cholesterol levels in its phase IIb study on its lead pipeline candidate, obeticholic acid (OCA) when it came out with a press release on Jan 9. Intercept Pharmaceuticals Inc (NASDAQ:ICPT) shares moved down -2.42% in last trading session and was closed at $217.94, while trading in range of $215.02 – $233.00. Intercept Pharmaceuticals Inc (NASDAQ:ICPT) year to date (YTD) performance is 219.19%.
Auspex Pharmaceuticals Inc (NASDAQ:ASPX) posted its quarterly earnings results on Tuesday. The company reported ($0.81) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.39) by $0.42. The clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, on 12 May 2014 reported financial results for first quarter 2014 and provided an update on the Company’s business highlights. The RoclatanTM Phase 2b clinical trial is advancing rapidly, with public release of efficacy data now expected in late June or early July 2014. The RhopressaTM Phase 3 registration trials are on schedule and planned to commence early third quarter 2014, with efficacy data expected mid-2015, and NDA filing currently projected for mid-2016. Company ended the first quarter of 2014 with over $65 million of cash and short-term investments on its balance sheet. This amount is expected to fund Rhopressa™ Phase 3 development through NDA filing and Roclatan™ development through completion of the Phase 2b trial and including subsequent follow-on Phase 3 preparatory activities.
Aerie Pharmaceuticals Inc (NASDAQ:AERI) weekly performance is -8.15%. On last trading day company shares ended up $15.22. Analysts mean target price for the company is $26.25. Aerie Pharmaceuticals Inc (NASDAQ:AERI) distance from 50-day simple moving average (SMA50) is -14.90%.
Leave a Reply